Excellent execution does not mean the right problem is being solved.
Drug development organizations are very good at solving difficult problems.
They can design sophisticated trials, generate enormous amounts of data, manage increasingly ...
Selected Perspectives
Healthcare investors who underweight clinical execution risk do not just miss upside. They inherit the downstream consequences of assumptions made too early.
Private equity and venture capital now shape significant portions of healthcare ...
Most healthcare investments fail due to clinical execution risk, not flawed science or market assumptions. A Sentikon perspective on what investors overlook.
Effective translational strategy reduces downstream failure by aligning science, endpoints, and execution from the start.
Most healthcare failures are not scientific; they result from underestimating clinical execution risk early.
Technical performance does not translate into impact without workflow alignment, evidence credibility, and governance.
Fractional leadership creates value only when it brings true decision authority, not advisory noise.
In crowded markets, the quality and credibility of evidence, not novelty, determines adoption and value.
No results found.